Canada markets closed

GSK plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
45.07+0.40 (+0.90%)
At close: 04:00PM EDT
44.97 -0.10 (-0.22%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close44.67
Open44.98
Bid45.03 x 800
Ask45.25 x 2900
Day's Range44.80 - 45.10
52 Week Range33.33 - 45.10
Volume3,651,278
Avg. Volume3,342,456
Market Cap92.714B
Beta (5Y Monthly)0.27
PE Ratio (TTM)16.57
EPS (TTM)2.72
Earnings DateJul 31, 2024
Forward Dividend & Yield1.50 (3.37%)
Ex-Dividend DateMay 16, 2024
1y Target Est45.79
  • Bloomberg

    Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down

    (Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th

  • Simply Wall St.

    GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

    GSK plc's ( LON:GSK ) investors are due to receive a payment of £0.15 per share on 11th of July. The dividend yield...

  • GlobeNewswire

    BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

    Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections